Marton Laurence 4

What Happened

• Marton Laurence, a director of RenovoRx, reported purchases in a private placement on March 20, 2026. The filing shows acquisition of 9,720 common shares and a derivative package representing 4,860 shares (warrants), with aggregate consideration of $10,000. The filing lists no per‑share price; the aggregate consideration for the securities was $10,000.

Key Details

• Transaction date: March 20, 2026; Form 4 filed March 24, 2026 (timely within the 2-business-day rule).
• Transaction type: P = Purchase (private placement).
• Shares acquired: 9,720 common shares; 4,860 derivative securities (warrants) tied to common shares.
• Aggregate purchase price: $10,000 for the securities purchased in the private placement (per-footnote). The implied average price is roughly $0.69 per unit (aggregate divided by total units), though no per‑security price is stated in the filing.
• Shares owned after the transaction: Not disclosed in the supplied filing details.
• Footnotes of note:
  • F1: Confirms the securities were purchased in a private placement on March 20, 2026 for an aggregate $10,000.
  • F2: The derivative securities are warrants exercisable immediately and expiring on the earlier of (i) March 30, 2029 or (ii) 30 days after the issuer reports at least $1.5M in product sales revenue for any quarter (sales revenue definition excludes certain non‑sales items).
• Filing timeliness: Filed within the required 2 business days following the transaction (no late filing indicated).

Context

• This was an insider purchase (often considered a more informative signal than routine sales because it increases the insider's stake), but the filing provides limited detail on post‑transaction ownership or the economic terms beyond the aggregate $10,000. The 4,860 derivative units appear to be warrants that can be exercised immediately but have a revenue‑linked earlier expiration trigger as described in the footnote.